
Review compares epigenetic drugs with chemotherapy in relapsed T-cell lymphoma
This meta-analysis examined 38 studies involving 2,170 people with relapsed or treatment-resistant peripheral T-cell lymphoma. Regimens containing an epigenetic drug had tumor response rates similar to conventional chemotherapy, but the studies reported higher one-year progression-free and overall survival rates with the epigenetic-containing regimens. Because the comparisons were based mainly on separate cohorts rather than randomized trials, the results show an association rather than proof that one approach caused better outcomes.

